AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
SAN ANTONIO -- The dopamine-3 receptor agonist pramipexole significantly improved pain, function, and fatigue in patients with severe, longstanding fibromyalgia, Andrew J. Holman, M.D., said in a late-breaking abstract session at the annual meeting of the American College of Rheumatology.
In a double blind, randomized, placebo controlled clinical trial that included 60 patients, pain as measured on a 10-point visual analog scale (VAS) improved by 36%, from a mean score of 7.0 at baseline to 4.5 after 14 weeks of treatment with pramipexole.
By contrast, patients receiving placebo experienced only a 9% decrease in pain, from 7.54 to 6.82. At baseline, all…
Source: HighBeam Research, Fibromyalgia pain responds to dopamine-3 receptor...